氯化奥昔布宁制剂的比较综述：膀胱过度活动症的药代动力学和治疗效果
A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder.
作者信息
Kennelly Michael J
机构信息
McKay Department of Urology, Carolinas Medical Center Charlotte, NC.
出版信息
Rev Urol. 2010 Winter;12(1):12-9.
Abstract
Antimuscarinic agents remain the mainstay of treatment of overactive bladder. However, the utility of some of these agents is limited due to tolerability concerns, multiple daily dosage regimens, lack of formulary coverage, and high cost. This can lead to problems with long-term compliance and may preclude optimal management. Oxybutynin has been the most widely prescribed antimuscarinic agent for more than 30 years. To meet the needs of tolerability and compliance, oxybutynin has evolved from an immediate-release pill to a once-daily oral dose and is now available as a topical gel. This review compares the various oxybutynin formulations in terms of pharmacokinetics, efficacy, and tolerability issues.
摘要
抗毒蕈碱药物仍然是治疗膀胱过度活动症的主要药物。然而，由于耐受性问题、每日多次给药方案、缺乏医保覆盖以及成本高昂，其中一些药物的效用受到限制。这可能导致长期依从性问题，并可能妨碍最佳治疗。30多年来，奥昔布宁一直是处方最广泛的抗毒蕈碱药物。为满足耐受性和依从性的需求，奥昔布宁已从速释片发展为每日一次口服剂型，现在还有外用凝胶剂型。本综述从药代动力学、疗效和耐受性问题方面比较了各种奥昔布宁制剂。
相似文献
1
2
Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.
Eur Urol. 2002 Jan;41(1):6-14. doi: 10.1016/s0302-2838(01)00009-4.
3
Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.奥昔布宁治疗急迫性尿失禁和膀胱过度活动症：最新综述
Expert Opin Pharmacother. 2004 Nov;5(11):2351-9. doi: 10.1517/14656566.5.11.2351.
4
Oxybutynin extended-release: a review of its use in the management of overactive bladder.奥昔布宁缓释制剂：用于治疗膀胱过度活动症的综述
Drugs. 2004;64(8):885-912. doi: 10.2165/00003495-200464080-00011.
5
Development of oxybutynin chloride topical gel for overactive bladder.用于膀胱过度活动症的氯化奥昔布宁外用凝胶的研发。
Open Access J Urol. 2011 Apr 4;3:35-42. doi: 10.2147/OAJU.S17046.
6
Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.盐酸奥昔布宁局部凝胶：一种用于治疗膀胱过度活动症的成熟抗毒蕈碱药物的新配方。
Expert Opin Pharmacother. 2009 Dec;10(18):3103-11. doi: 10.1517/14656560903451682.
7
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.每日一次 5 毫克索利那新与每日三次 5 毫克奥昔布宁速释制剂的耐受性比较：VECTOR 试验结果。
J Urol. 2010 May;183(5):1892-8. doi: 10.1016/j.juro.2010.01.012. Epub 2010 Mar 29.
8
The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy.经皮/局部膀胱过度活动症治疗的进展及其相对于口服治疗的优势。
Rev Obstet Gynecol. 2009 Spring;2(2):116-21.
9
The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy.经皮/局部膀胱过度活动症治疗的进展及其相对于口服治疗的优势。
Rev Urol. 2009 Winter;11(1):1-6.
10
Oxybutynin topical and transdermal formulations: an update.奥昔布宁局部用和透皮制剂：最新进展
Drugs Today (Barc). 2010 Jun;46(6):417-25. doi: 10.1358/dot.2010.46.6.1487750.
引用本文的文献
1
First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring.首个人体研究评估经微处理器控制的阴道环给予单剂量盐酸奥昔布宁的药代动力学、耐受性和安全性。
Drug Deliv. 2023 Dec;30(1):2180113. doi: 10.1080/10717544.2023.2180113.
2
Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome.羟丁宁与肉毒杆菌毒素 A（保妥适）治疗膀胱过度活动症的成本效用分析。
Int J Environ Res Public Health. 2021 Aug 19;18(16):8743. doi: 10.3390/ijerph18168743.
3
Drug Delivery Approaches for Managing Overactive Bladder (OAB): A Systematic Review.治疗膀胱过度活动症（OAB）的药物递送方法：一项系统评价
Pharmaceuticals (Basel). 2021 Apr 26;14(5):409. doi: 10.3390/ph14050409.
4
Metabolic -Dealkylation and -Oxidation as Elucidators of the Role of Alkylamino Moieties in Drugs Acting at Various Receptors.代谢脱烷基化和氧化在阐明各种受体作用的药物中氨基烷基部分的作用。
Molecules. 2021 Mar 29;26(7):1917. doi: 10.3390/molecules26071917.
5
Polypharmacy Results in Functional Impairment in Mice: Novel Insights Into Age and Sex Interactions.多药治疗导致小鼠功能障碍：年龄和性别相互作用的新见解。
J Gerontol A Biol Sci Med Sci. 2021 Sep 13;76(10):1748-1756. doi: 10.1093/gerona/glab088.
6
Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.在美国，采用联合口服治疗、骶神经刺激、经皮胫神经刺激或肉毒毒素 A 治疗的 OAB 患者的治疗模式和费用。
Neurourol Urodyn. 2020 Nov;39(8):2206-2222. doi: 10.1002/nau.24474. Epub 2020 Aug 22.
7
Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products.渗透泵产品的基于生理学的药代动力学和吸收建模。
AAPS J. 2017 Jul;19(4):1045-1053. doi: 10.1208/s12248-017-0075-7. Epub 2017 Mar 29.
8
Trends in Pharmacotherapy for Bladder Dysfunction Among Children in the United States, 2000 to 2013.2000年至2013年美国儿童膀胱功能障碍药物治疗趋势
Clin Pediatr (Phila). 2017 Jan;56(1):55-64. doi: 10.1177/0009922816641366. Epub 2016 Jul 19.
9
Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin.老年女性膀胱过度活动症的治疗：曲司氯铵、奥昔布宁、非索罗定和达非那新的应用情况
Drugs Aging. 2015 Oct;32(10):809-19. doi: 10.1007/s40266-015-0301-x.
10
Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.成人膀胱过度活动症的药物治疗：疗效、耐受性及生活质量综述
Res Rep Urol. 2013 Dec 6;6:1-16. doi: 10.2147/RRU.S40034.
本文引用的文献
1
Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence.口服缓释奥昔布宁对患有急迫性尿失禁的认知障碍养老院居民认知效果、安全性及耐受性的随机安慰剂对照试验
J Am Geriatr Soc. 2008 May;56(5):862-70. doi: 10.1111/j.1532-5415.2008.01680.x. Epub 2008 Apr 9.
2
Overactive bladder: treatment options in primary care medicine.
J Am Osteopath Assoc. 2007 Sep;107(9):379-85.
3
Management of overactive bladder with transdermal oxybutynin.经皮奥昔布宁治疗膀胱过度活动症
Rev Urol. 2006 Summer;8(3):93-103.
4
Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.抗毒蕈碱药物达非那新和奥昔布宁缓释剂对老年受试者记忆力的不同影响。
Eur Urol. 2006 Aug;50(2):317-26. doi: 10.1016/j.eururo.2006.03.057. Epub 2006 Apr 19.
5
Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery.
Expert Opin Drug Deliv. 2005 Sep;2(5):935-50. doi: 10.1517/17425247.2.5.935.
6
Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.提高抗胆碱能药物治疗膀胱过度活动症的耐受性。
Drug Saf. 2005;28(7):583-600. doi: 10.2165/00002018-200528070-00003.
7
A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence.
Clin Ther. 2004 Jul;26(7):1026-36. doi: 10.1016/s0149-2918(04)90174-9.
8
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.健康受试者经皮给药和口服缓释奥昔布宁期间的药代动力学、代谢及唾液分泌量
Mayo Clin Proc. 2003 Jun;78(6):696-702. doi: 10.4065/78.6.696.
9
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.奥昔布宁和托特罗定缓释制剂治疗膀胱过度活动症疗效和耐受性的前瞻性、随机、双盲研究：OPERA试验结果
Mayo Clin Proc. 2003 Jun;78(6):687-95. doi: 10.4065/78.6.687.
10
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.
Urology. 2003 Aug;62(2):237-42. doi: 10.1016/s0090-4295(03)00356-x.
Zotero 插件